Does the media favor PRCT or TMCI?

In the previous week, PROCEPT BioRobotics had 20 more articles in the media than Treace Medical Concepts. MarketBeat recorded 27 mentions for PROCEPT BioRobotics and 7 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 0.78 beat PROCEPT BioRobotics' score of 0.01 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 2 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Treace Medical Concepts 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TNDM or TMCI?

In the previous week, Treace Medical Concepts had 4 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 7 mentions for Treace Medical Concepts and 3 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.48 beat Treace Medical Concepts' score of 0.78 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Treace Medical Concepts 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TMCI or STAA?

In the previous week, Treace Medical Concepts had 3 more articles in the media than STAAR Surgical. MarketBeat recorded 7 mentions for Treace Medical Concepts and 4 mentions for STAAR Surgical. Treace Medical Concepts' average media sentiment score of 0.78 beat STAAR Surgical's score of 0.37 indicating that Treace Medical Concepts is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STAAR Surgical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BVS or TMCI?

In the previous week, Treace Medical Concepts had 5 more articles in the media than Bioventus. MarketBeat recorded 7 mentions for Treace Medical Concepts and 2 mentions for Bioventus. Bioventus' average media sentiment score of 1.87 beat Treace Medical Concepts' score of 0.78 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Treace Medical Concepts 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRMD or TMCI?

In the previous week, Treace Medical Concepts had 5 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for Treace Medical Concepts and 2 mentions for iRadimed. Treace Medical Concepts' average media sentiment score of 0.78 beat iRadimed's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Treace Medical Concepts 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Treace Medical Concepts (TMCI) Competitors

$4.51 -0.08 (-1.74%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.41 -0.10 (-2.31%)

As of 07:00 AM Eastern

Compare

TMCI vs. PRCT, TNDM, STAA, BVS, and IRMD

Should you buy Treace Medical Concepts stock or one of its competitors? Treace Medical Concepts's main competitors and comparable companies include PROCEPT BioRobotics (PRCT), Tandem Diabetes Care (TNDM), STAAR Surgical (STAA), Bioventus (BVS), and iRadimed (IRMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Treace Medical Concepts compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

PROCEPT BioRobotics currently has a consensus target price of $25.09, indicating a potential upside of 38.70%. Treace Medical Concepts has a consensus target price of $5.17, indicating a potential upside of 14.63%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.20
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

In the previous week, PROCEPT BioRobotics had 20 more articles in the media than Treace Medical Concepts. MarketBeat recorded 27 mentions for PROCEPT BioRobotics and 7 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 0.78 beat PROCEPT BioRobotics' score of 0.01 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	2 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Treace Medical Concepts	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Treace Medical Concepts has a net margin of -28.99% compared to PROCEPT BioRobotics' net margin of -32.53%. PROCEPT BioRobotics' return on equity of -30.62% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

PROCEPT BioRobotics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Treace Medical Concepts has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	3.36	-$95.57M	-$1.94	N/A
Treace Medical Concepts	$212.69M	1.38	-$59M	-$0.93	N/A

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

PROCEPT BioRobotics beats Treace Medical Concepts on 10 of the 17 factors compared between the two stocks.

How does Treace Medical Concepts compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

In the previous week, Treace Medical Concepts had 4 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 7 mentions for Treace Medical Concepts and 3 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.48 beat Treace Medical Concepts' score of 0.78 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Treace Medical Concepts	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Treace Medical Concepts has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.12	-$204.71M	-$0.93	N/A
Treace Medical Concepts	$212.69M	1.38	-$59M	-$0.93	N/A

Tandem Diabetes Care has a net margin of -6.08% compared to Treace Medical Concepts' net margin of -28.99%. Tandem Diabetes Care's return on equity of -45.97% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

84.1% of Treace Medical Concepts shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tandem Diabetes Care has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Tandem Diabetes Care presently has a consensus target price of $29.34, suggesting a potential upside of 79.13%. Treace Medical Concepts has a consensus target price of $5.17, suggesting a potential upside of 14.63%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, equities analysts plainly believe Tandem Diabetes Care is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

Summary

Tandem Diabetes Care beats Treace Medical Concepts on 10 of the 16 factors compared between the two stocks.

How does Treace Medical Concepts compare to STAAR Surgical?

Treace Medical Concepts (NASDAQ:TMCI) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Treace Medical Concepts has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by company insiders. Comparatively, 39.9% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Treace Medical Concepts had 3 more articles in the media than STAAR Surgical. MarketBeat recorded 7 mentions for Treace Medical Concepts and 4 mentions for STAAR Surgical. Treace Medical Concepts' average media sentiment score of 0.78 beat STAAR Surgical's score of 0.37 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Treace Medical Concepts	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STAAR Surgical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

STAAR Surgical has a net margin of 1.13% compared to Treace Medical Concepts' net margin of -28.99%. STAAR Surgical's return on equity of 9.05% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-28.99%	-71.37%	-30.49%
STAAR Surgical	1.13%	9.05%	6.99%

Treace Medical Concepts currently has a consensus price target of $5.17, indicating a potential upside of 14.63%. STAAR Surgical has a consensus price target of $27.90, indicating a potential upside of 40.91%. Given STAAR Surgical's stronger consensus rating and higher probable upside, analysts clearly believe STAAR Surgical is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
STAAR Surgical	3 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Treace Medical Concepts has higher earnings, but lower revenue than STAAR Surgical. Treace Medical Concepts is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.38	-$59M	-$0.93	N/A
STAAR Surgical	$339.59M	2.92	-$80.45M	$0.07	282.86

Summary

STAAR Surgical beats Treace Medical Concepts on 12 of the 16 factors compared between the two stocks.

How does Treace Medical Concepts compare to Bioventus?

Bioventus (NASDAQ:BVS) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Treace Medical Concepts had 5 more articles in the media than Bioventus. MarketBeat recorded 7 mentions for Treace Medical Concepts and 2 mentions for Bioventus. Bioventus' average media sentiment score of 1.87 beat Treace Medical Concepts' score of 0.78 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Treace Medical Concepts	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has higher revenue and earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.01	$22.73M	$0.77	17.68
Treace Medical Concepts	$212.69M	1.38	-$59M	-$0.93	N/A

Bioventus has a net margin of 9.36% compared to Treace Medical Concepts' net margin of -28.99%. Bioventus' return on equity of 28.08% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

Bioventus has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Bioventus currently has a consensus price target of $16.80, indicating a potential upside of 23.44%. Treace Medical Concepts has a consensus price target of $5.17, indicating a potential upside of 14.63%. Given Bioventus' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bioventus is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

62.9% of Bioventus shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 33.5% of Bioventus shares are held by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Bioventus beats Treace Medical Concepts on 13 of the 16 factors compared between the two stocks.

How does Treace Medical Concepts compare to iRadimed?

iRadimed (NASDAQ:IRMD) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 34.6% of iRadimed shares are owned by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

iRadimed has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

iRadimed currently has a consensus target price of $120.00, indicating a potential upside of 38.97%. Treace Medical Concepts has a consensus target price of $5.17, indicating a potential upside of 14.63%. Given iRadimed's stronger consensus rating and higher possible upside, equities research analysts clearly believe iRadimed is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

In the previous week, Treace Medical Concepts had 5 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for Treace Medical Concepts and 2 mentions for iRadimed. Treace Medical Concepts' average media sentiment score of 0.78 beat iRadimed's score of 0.00 indicating that Treace Medical Concepts is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Treace Medical Concepts	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.18	$22.48M	$1.79	48.24
Treace Medical Concepts	$212.69M	1.38	-$59M	-$0.93	N/A

iRadimed has a net margin of 26.70% compared to Treace Medical Concepts' net margin of -28.99%. iRadimed's return on equity of 23.45% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

Summary

iRadimed beats Treace Medical Concepts on 13 of the 17 factors compared between the two stocks.

Get Treace Medical Concepts News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMCI vs. The Competition

Export

Metric	Treace Medical Concepts	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$298.51M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-4.85	25.26	274.08	25.69
Price / Sales	1.38	71.56	638.21	78.99
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	3.29	5.78	10.47	6.32
Net Income	-$59M	$151.55M	$3.49B	$359.73M
7 Day Performance	-0.44%	-0.01%	-0.67%	0.17%
1 Month Performance	3.20%	-3.53%	-3.17%	-3.27%
1 Year Performance	-33.48%	6.37%	15.14%	5.58%

Treace Medical Concepts Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMCI Treace Medical Concepts	2.9018 of 5 stars	$4.51 -1.7%	$5.17 +14.6%	-33.7%	$298.51M	$212.69M	N/A	450
PRCT PROCEPT BioRobotics	4.0781 of 5 stars	$19.30 -8.2%	$25.09 +30.0%	-53.8%	$1.20B	$308.05M	N/A	888
TNDM Tandem Diabetes Care	2.5487 of 5 stars	$16.28 -3.2%	$29.34 +80.2%	+28.3%	$1.17B	$1.01B	N/A	2,500	Positive News
STAA STAAR Surgical	3.3664 of 5 stars	$22.44 -2.7%	$28.40 +26.6%	-25.4%	$1.16B	$239.44M	320.62	957	News Coverage Analyst Forecast
BVS Bioventus	4.2908 of 5 stars	$13.00 -1.2%	$16.80 +29.2%	+96.7%	$1.11B	$568.09M	16.88	950	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMCI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Treace Medical Concepts (TMCI) Competitors

TMCI vs. PRCT, TNDM, STAA, BVS, and IRMD

How does Treace Medical Concepts compare to PROCEPT BioRobotics?

Summary

How does Treace Medical Concepts compare to Tandem Diabetes Care?

Summary

How does Treace Medical Concepts compare to STAAR Surgical?

Summary

How does Treace Medical Concepts compare to Bioventus?

Summary

How does Treace Medical Concepts compare to iRadimed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMCI vs. The Competition

Treace Medical Concepts Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Treace Medical Concepts (TMCI) Competitors

TMCI vs. PRCT, TNDM, STAA, BVS, and IRMD

How does Treace Medical Concepts compare to PROCEPT BioRobotics?

Do analysts recommend PRCT or TMCI?

Does the media favor PRCT or TMCI?

Is PRCT or TMCI more profitable?

Which has more risk and volatility, PRCT or TMCI?

Which has better valuation & earnings, PRCT or TMCI?

Do insiders & institutionals have more ownership in PRCT or TMCI?

Summary

How does Treace Medical Concepts compare to Tandem Diabetes Care?

Does the media favor TNDM or TMCI?

Which has preferable valuation & earnings, TNDM or TMCI?

Is TNDM or TMCI more profitable?

Do institutionals & insiders hold more shares of TNDM or TMCI?

Which has more risk & volatility, TNDM or TMCI?

Do analysts recommend TNDM or TMCI?

Summary

How does Treace Medical Concepts compare to STAAR Surgical?

Which has more risk & volatility, TMCI or STAA?

Do institutionals and insiders have more ownership in TMCI or STAA?

Does the media refer more to TMCI or STAA?

Is TMCI or STAA more profitable?

Do analysts rate TMCI or STAA?

Which has better valuation and earnings, TMCI or STAA?

Summary

How does Treace Medical Concepts compare to Bioventus?

Does the media favor BVS or TMCI?

Which has better valuation and earnings, BVS or TMCI?

Is BVS or TMCI more profitable?

Which has more volatility & risk, BVS or TMCI?

Do analysts rate BVS or TMCI?

Do institutionals & insiders have more ownership in BVS or TMCI?

Summary

How does Treace Medical Concepts compare to iRadimed?

Do insiders & institutionals believe in IRMD or TMCI?

Which has more volatility & risk, IRMD or TMCI?

Do analysts prefer IRMD or TMCI?

Does the media prefer IRMD or TMCI?

Which has better earnings and valuation, IRMD or TMCI?

Is IRMD or TMCI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMCI vs. The Competition

Treace Medical Concepts Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools